# Lumexa Imaging Holdings, Inc. (LMRI)

> Source: Nexqual · https://nexqual.com/LMRI · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Lumexa Imaging Holdings, Inc. (LMRI), nexqual.com/LMRI" · informational, not investment advice.

**Price:** USD 11.73 (+0.95% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 11.62 · day 11.53–11.87 · 52w 6.45–19.45 · market cap $1.13B · NMS

## Key facts
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $477K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.80 on a 1–5 scale) (10 analysts), mean target USD 17.67 (range 13–23).
- Total return with dividends: 1Y -37.3% vs S&P 500 +14.8%; 5Y -36.7% vs S&P 500 +79.1%.
- Next earnings: 2026-11-10, EPS estimate USD 0.18, revenue estimate $270M. All companies reporting that day: https://nexqual.com/earnings/2026-11-10
- Dividend: LMRI paid no cash dividend in the last five years.
- Short interest: 7.44% of float (as of 2026-10-15), 4.6 days to cover.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 1.1x · EV/EBITDA 14.1x · EV/Sales 1.9x · P/FCF 346.0x · P/B 1.8x · FCF yield 0.29% · Earnings yield -0.93% · Net debt $766M · EV $1.89B

## Insider purchases (SEC Form 4, open-market, last ~7 months)
2 purchases, $477K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-19 | Brodnax Brett | Director | 35,000 | $254K | 7.25 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-14 | Cooper Henry Lee | Director | 30,000 | $223K | 7.44 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.80 on a 1–5 scale), 10 analysts; mean target USD 17.67 (low 13, high 23).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | Truist Securities | Initiated | Buy | $18 |
| 2026-09-25 | Keybanc | Initiated | Overweight | $18 |
| 2026-08-28 | Barclays | Target raised | Overweight | $9 → $13 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-12-11) | 5Y (from 2025-12-08) |
|---|---|---|
| Total return | -37.3% | -36.7% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | — | — |
| Volatility (annualized) | 78.6% | 89.0% |
| Max drawdown | -63.5% (Dec 2025→May 2026) | -62.1% (Dec 2025→May 2026) |

## Dividends
LMRI paid no cash dividend in the last five years.

## Short interest
1,918,493 shares sold short, 7.44% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 2,126,195 shares (-9.8%). Days to cover: 4.6 (short shares ÷ average daily volume).

## Peers (Medical Devices)
INSP (Inspire Medical Systems, Inc.) USD 71.18 +0.30% · ESTA (Establishment Labs Holdings Inc) USD 68.41 -0.81% · BFLY (Butterfly Network, Inc.) USD 7.51 -3.84% · UFPT (UFP Technologies, Inc.) USD 293.3 +2.55% · TMDX (TransMedics Group, Inc.) USD 67.12 +0.33% · ALMR (Alamar Biosciences, Inc.) USD 34.04 -0.76%

## More
Full page: https://nexqual.com/LMRI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Outpatient | $196.2M | 74.3% | +4.8% |
| Professional | $72.2M | 27.3% | +8.9% |
| Total revenue | $264.2M | 100% | — |
The lines above cover 101.6% of total revenue.

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Health Care Patient Service | $194.9M | 73.8% | +2.9% |
| Management Fee & Other Revenue | $52.5M | 19.9% | +8.6% |
| Management Fee & Other Revenue Related Party | $51.7M | 19.6% | +6.9% |
| Patient Service Revenue Related Party | $8.8M | 3.3% | -0.1% |
| Investment Advisory Management & Administrative Service | $8.7M | 3.3% | +80.6% |
| Total revenue | $264.2M | 100% | — |
The lines above cover 119.9% of total revenue.

## Company outlook (8-K filed 2026-08-12)

- "Full Year Outlook: Lumexa Imaging provided an update on its guidance for the full year ended December 31, 2026. • Reiterating full-year 2026 consolidated revenue guidance of $1.045 billion to $1.097 billion. • Narrowing its full-year 2026 Adjusted EBITDA guidance range to $235 million to $241 million, from its prior range of $234 million to $242 million."
- "(At the midpoint of guidance, the addition of these costs lowers Adjusted EBITDA growth for 2026 versus 2025 from 7% to 4%) • Reiterating guidance for Adjusted EPS of $0.71 to $0.77 per share."
- "Lumexa Imaging Earnings Conference Call and Webcast Lumexa Imaging will host a conference call to discuss its second quarter 2026 results, as well as its 2026 outlook, on August 12, 2026 at 5:00 p.m."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.18 | $0.19 | -5.2% | $269.9M | 8 |
| Next quarter (ends 2026-12-31) | $0.21 | $0.23 | -7.8% | $280.1M | 8 |
| Current fiscal year (ends 2026-12-31) | $0.77 | $0.71 | +8.5% | $1.07B | 8 |
| Next fiscal year (ends 2027-12-31) | $0.89 | $0.90 | -1.1% | $1.12B | 8 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.20 | $0.14 | Beat +42.9% | — |
| — | Quarter ended Dec 31, 2025 | $0.01 | $0.05 | Miss −80.0% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-08-14 | Schedule 13G | BROWN ADVISORY INC, BROWN INVESTMENT ADVISORY & TRUST CO: 6.1% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/2071288/000134592926000033/0001345929-26-000033-index.htm |
| 2026-08-13 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/2071288/000119312526348902/0001193125-26-348902-index.htm |
| 2026-08-12 | 8-K | Quarterly results; Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/2071288/000119312526346813/0001193125-26-346813-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.